Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 2 of 2 results for brolucizumab wet age-related macular degeneration

  1. Brolucizumab for treating wet age-related macular degeneration (TA672)

    Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    3 February 2021
    View recommendations

    Sections for TA672

  2. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820